nodes	percent_of_prediction	percent_of_DWPC	metapath
Valrubicin—TOP2A—Paclitaxel—Docetaxel—melanoma	0.0472	1	CbGdCrCtD
Valrubicin—Epirubicin—AURKA—melanoma	0.0371	0.4	CrCbGaD
Valrubicin—Local reaction—Bleomycin—melanoma	0.024	0.0434	CcSEcCtD
Valrubicin—Doxorubicin—AURKA—melanoma	0.0213	0.23	CrCbGaD
Valrubicin—Cystitis noninfective—Bleomycin—melanoma	0.013	0.0235	CcSEcCtD
Valrubicin—Cystitis—Bleomycin—melanoma	0.0128	0.0232	CcSEcCtD
Valrubicin—Bladder pain—Bleomycin—melanoma	0.012	0.0217	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 1—AURKA—melanoma	0.0117	0.038	CbGpPWpGaD
Valrubicin—Urinary incontinence—Carmustine—melanoma	0.0112	0.0203	CcSEcCtD
Valrubicin—Oedema peripheral—Vemurafenib—melanoma	0.0108	0.0196	CcSEcCtD
Valrubicin—Urinary incontinence—Temozolomide—melanoma	0.0108	0.0196	CcSEcCtD
Valrubicin—Daunorubicin—CYP1B1—melanoma	0.0104	0.113	CrCbGaD
Valrubicin—Doxorubicin—NOS2—melanoma	0.00997	0.108	CrCbGaD
Valrubicin—TOP2A—Circadian rythm related genes—RAI1—melanoma	0.00971	0.0315	CbGpPWpGaD
Valrubicin—Back pain—Vemurafenib—melanoma	0.00927	0.0168	CcSEcCtD
Valrubicin—Ageusia—Docetaxel—melanoma	0.00919	0.0167	CcSEcCtD
Valrubicin—TOP2A—G0 and Early G1—E2F1—melanoma	0.0091	0.0295	CbGpPWpGaD
Valrubicin—TOP2A—G0 and Early G1—PCNA—melanoma	0.00858	0.0279	CbGpPWpGaD
Valrubicin—Doxorubicin—CYP1B1—melanoma	0.00847	0.0914	CrCbGaD
Valrubicin—Myalgia—Vemurafenib—melanoma	0.00816	0.0148	CcSEcCtD
Valrubicin—TOP2A—G0 and Early G1—CDK2—melanoma	0.00785	0.0255	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—FASN—melanoma	0.00779	0.0253	CbGpPWpGaD
Valrubicin—Pneumonia—Bleomycin—melanoma	0.00747	0.0135	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—PKMYT1—melanoma	0.00742	0.0241	CbGpPWpGaD
Valrubicin—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00712	0.0129	CcSEcCtD
Valrubicin—Haematuria—Bleomycin—melanoma	0.00708	0.0128	CcSEcCtD
Valrubicin—Pneumonia—Dactinomycin—melanoma	0.00697	0.0126	CcSEcCtD
Valrubicin—Dysuria—Temozolomide—melanoma	0.00657	0.0119	CcSEcCtD
Valrubicin—Hyperglycaemia—Carmustine—melanoma	0.00656	0.0119	CcSEcCtD
Valrubicin—Pneumonia—Carmustine—melanoma	0.00652	0.0118	CcSEcCtD
Valrubicin—Pollakiuria—Temozolomide—melanoma	0.00649	0.0118	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 1—NOTCH1—melanoma	0.00634	0.0206	CbGpPWpGaD
Valrubicin—Hyperglycaemia—Temozolomide—melanoma	0.00634	0.0115	CcSEcCtD
Valrubicin—Urinary tract infection—Carmustine—melanoma	0.0063	0.0114	CcSEcCtD
Valrubicin—Pneumonia—Temozolomide—melanoma	0.0063	0.0114	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 1—APC—melanoma	0.0062	0.0201	CbGpPWpGaD
Valrubicin—Body temperature increased—Vemurafenib—melanoma	0.00618	0.0112	CcSEcCtD
Valrubicin—Urinary tract infection—Temozolomide—melanoma	0.00609	0.011	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—VDR—melanoma	0.00583	0.0189	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—ARNT—melanoma	0.00577	0.0187	CbGpPWpGaD
Valrubicin—Oedema peripheral—Carmustine—melanoma	0.00573	0.0104	CcSEcCtD
Valrubicin—Asthenia—Vemurafenib—melanoma	0.00561	0.0102	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—PAX4—melanoma	0.00558	0.0181	CbGpPWpGaD
Valrubicin—Oedema peripheral—Temozolomide—melanoma	0.00554	0.01	CcSEcCtD
Valrubicin—Pruritus—Vemurafenib—melanoma	0.00553	0.01	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CAPN1—melanoma	0.00546	0.0177	CbGpPWpGaD
Valrubicin—Ill-defined disorder—Bleomycin—melanoma	0.00539	0.00976	CcSEcCtD
Valrubicin—Anaemia—Bleomycin—melanoma	0.00537	0.00972	CcSEcCtD
Valrubicin—Diarrhoea—Vemurafenib—melanoma	0.00535	0.00969	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—SKP2—melanoma	0.00532	0.0173	CbGpPWpGaD
Valrubicin—Malaise—Bleomycin—melanoma	0.00523	0.00948	CcSEcCtD
Valrubicin—Dizziness—Vemurafenib—melanoma	0.00517	0.00937	CcSEcCtD
Valrubicin—Ill-defined disorder—Dactinomycin—melanoma	0.00502	0.0091	CcSEcCtD
Valrubicin—Anaemia—Dactinomycin—melanoma	0.005	0.00906	CcSEcCtD
Valrubicin—Vomiting—Vemurafenib—melanoma	0.00497	0.00901	CcSEcCtD
Valrubicin—Myalgia—Bleomycin—melanoma	0.00494	0.00895	CcSEcCtD
Valrubicin—Chest pain—Bleomycin—melanoma	0.00494	0.00895	CcSEcCtD
Valrubicin—Rash—Vemurafenib—melanoma	0.00493	0.00893	CcSEcCtD
Valrubicin—Dermatitis—Vemurafenib—melanoma	0.00493	0.00892	CcSEcCtD
Valrubicin—Back pain—Carmustine—melanoma	0.0049	0.00888	CcSEcCtD
Valrubicin—Headache—Vemurafenib—melanoma	0.0049	0.00887	CcSEcCtD
Valrubicin—Discomfort—Bleomycin—melanoma	0.00488	0.00884	CcSEcCtD
Valrubicin—Malaise—Dactinomycin—melanoma	0.00488	0.00884	CcSEcCtD
Valrubicin—Back pain—Temozolomide—melanoma	0.00474	0.00858	CcSEcCtD
Valrubicin—Anaemia—Carmustine—melanoma	0.00468	0.00848	CcSEcCtD
Valrubicin—Nausea—Vemurafenib—melanoma	0.00464	0.00841	CcSEcCtD
Valrubicin—Myalgia—Dactinomycin—melanoma	0.00461	0.00835	CcSEcCtD
Valrubicin—Discomfort—Dactinomycin—melanoma	0.00455	0.00825	CcSEcCtD
Valrubicin—Ill-defined disorder—Temozolomide—melanoma	0.00454	0.00823	CcSEcCtD
Valrubicin—Anaemia—Temozolomide—melanoma	0.00453	0.0082	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—ATM—melanoma	0.0045	0.0146	CbGpPWpGaD
Valrubicin—Malaise—Temozolomide—melanoma	0.00442	0.008	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—NODAL—melanoma	0.0044	0.0143	CbGpPWpGaD
Valrubicin—Musculoskeletal discomfort—Bleomycin—melanoma	0.00432	0.00782	CcSEcCtD
Valrubicin—Chest pain—Carmustine—melanoma	0.00431	0.00781	CcSEcCtD
Valrubicin—Myalgia—Carmustine—melanoma	0.00431	0.00781	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—melanoma	0.00431	0.014	CbGpPWpGaD
Valrubicin—Pneumonia—Docetaxel—melanoma	0.00419	0.00759	CcSEcCtD
Valrubicin—Myalgia—Temozolomide—melanoma	0.00417	0.00755	CcSEcCtD
Valrubicin—Discomfort—Temozolomide—melanoma	0.00412	0.00746	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00403	0.00729	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—CTNNB1—melanoma	0.00399	0.013	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP10—melanoma	0.00392	0.0127	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAP3K5—melanoma	0.00392	0.0127	CbGpPWpGaD
Valrubicin—Feeling abnormal—Bleomycin—melanoma	0.0039	0.00707	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Carmustine—melanoma	0.00377	0.00682	CcSEcCtD
Valrubicin—Body temperature increased—Bleomycin—melanoma	0.00375	0.00678	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—SKP2—melanoma	0.00374	0.0122	CbGpPWpGaD
Valrubicin—Oedema peripheral—Docetaxel—melanoma	0.00369	0.00667	CcSEcCtD
Valrubicin—Feeling abnormal—Dactinomycin—melanoma	0.00364	0.00659	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Temozolomide—melanoma	0.00364	0.00659	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—DCC—melanoma	0.00362	0.0118	CbGpPWpGaD
Valrubicin—Gastrointestinal pain—Dactinomycin—melanoma	0.00361	0.00654	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—APAF1—melanoma	0.00352	0.0114	CbGpPWpGaD
Valrubicin—Body temperature increased—Dactinomycin—melanoma	0.00349	0.00633	CcSEcCtD
Valrubicin—Abdominal pain—Dactinomycin—melanoma	0.00349	0.00633	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—melanoma	0.00342	0.0111	CbGpPWpGaD
Valrubicin—Feeling abnormal—Carmustine—melanoma	0.00341	0.00617	CcSEcCtD
Valrubicin—Asthenia—Bleomycin—melanoma	0.0034	0.00616	CcSEcCtD
Valrubicin—Gastrointestinal pain—Carmustine—melanoma	0.00338	0.00612	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—E2F1—melanoma	0.00336	0.0109	CbGpPWpGaD
Valrubicin—Pruritus—Bleomycin—melanoma	0.00335	0.00607	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—melanoma	0.00334	0.0108	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—melanoma	0.00332	0.0108	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—REC8—melanoma	0.00332	0.0108	CbGpPWpGaD
Valrubicin—Feeling abnormal—Temozolomide—melanoma	0.00329	0.00596	CcSEcCtD
Valrubicin—Abdominal pain—Carmustine—melanoma	0.00327	0.00592	CcSEcCtD
Valrubicin—Body temperature increased—Carmustine—melanoma	0.00327	0.00592	CcSEcCtD
Valrubicin—Gastrointestinal pain—Temozolomide—melanoma	0.00327	0.00592	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—MYC—melanoma	0.00323	0.0105	CbGpPWpGaD
Valrubicin—Asthenia—Dactinomycin—melanoma	0.00317	0.00574	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—PCNA—melanoma	0.00316	0.0103	CbGpPWpGaD
Valrubicin—TOP2A—Gastric Cancer Network 2—EGFR—melanoma	0.00316	0.0103	CbGpPWpGaD
Valrubicin—Body temperature increased—Temozolomide—melanoma	0.00316	0.00572	CcSEcCtD
Valrubicin—Abdominal pain—Temozolomide—melanoma	0.00316	0.00572	CcSEcCtD
Valrubicin—Back pain—Docetaxel—melanoma	0.00315	0.00571	CcSEcCtD
Valrubicin—Diarrhoea—Dactinomycin—melanoma	0.00302	0.00548	CcSEcCtD
Valrubicin—Vomiting—Bleomycin—melanoma	0.00301	0.00546	CcSEcCtD
Valrubicin—Anaemia—Docetaxel—melanoma	0.00301	0.00545	CcSEcCtD
Valrubicin—Daunorubicin—ABCB1—melanoma	0.003	0.0323	CrCbGaD
Valrubicin—Rash—Bleomycin—melanoma	0.00299	0.00541	CcSEcCtD
Valrubicin—Dermatitis—Bleomycin—melanoma	0.00298	0.00541	CcSEcCtD
Valrubicin—Asthenia—Carmustine—melanoma	0.00297	0.00537	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDK2—melanoma	0.00289	0.0094	CbGpPWpGaD
Valrubicin—Asthenia—Temozolomide—melanoma	0.00287	0.00519	CcSEcCtD
Valrubicin—Diarrhoea—Carmustine—melanoma	0.00283	0.00512	CcSEcCtD
Valrubicin—Pruritus—Temozolomide—melanoma	0.00283	0.00512	CcSEcCtD
Valrubicin—Nausea—Bleomycin—melanoma	0.00281	0.0051	CcSEcCtD
Valrubicin—Vomiting—Dactinomycin—melanoma	0.00281	0.00509	CcSEcCtD
Valrubicin—Rash—Dactinomycin—melanoma	0.00279	0.00505	CcSEcCtD
Valrubicin—Myalgia—Docetaxel—melanoma	0.00277	0.00502	CcSEcCtD
Valrubicin—Chest pain—Docetaxel—melanoma	0.00277	0.00502	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—melanoma	0.00274	0.00888	CbGpPWpGaD
Valrubicin—Dizziness—Carmustine—melanoma	0.00273	0.00495	CcSEcCtD
Valrubicin—Diarrhoea—Temozolomide—melanoma	0.00273	0.00495	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—PKMYT1—melanoma	0.00272	0.00884	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—INCENP—melanoma	0.00272	0.00884	CbGpPWpGaD
Valrubicin—TOP2A—Gastric Cancer Network 2—TP53—melanoma	0.00266	0.00862	CbGpPWpGaD
Valrubicin—Dizziness—Temozolomide—melanoma	0.00264	0.00479	CcSEcCtD
Valrubicin—Vomiting—Carmustine—melanoma	0.00263	0.00476	CcSEcCtD
Valrubicin—Nausea—Dactinomycin—melanoma	0.00262	0.00475	CcSEcCtD
Valrubicin—Rash—Carmustine—melanoma	0.00261	0.00472	CcSEcCtD
Valrubicin—Dermatitis—Carmustine—melanoma	0.00261	0.00472	CcSEcCtD
Valrubicin—Headache—Carmustine—melanoma	0.00259	0.00469	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2B—melanoma	0.00257	0.00835	CbGpPWpGaD
Valrubicin—Vomiting—Temozolomide—melanoma	0.00254	0.0046	CcSEcCtD
Valrubicin—Rash—Temozolomide—melanoma	0.00252	0.00456	CcSEcCtD
Valrubicin—Dermatitis—Temozolomide—melanoma	0.00252	0.00456	CcSEcCtD
Valrubicin—Headache—Temozolomide—melanoma	0.0025	0.00453	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—GNA11—melanoma	0.00249	0.00809	CbGpPWpGaD
Valrubicin—Nausea—Carmustine—melanoma	0.00246	0.00445	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—INCENP—melanoma	0.00243	0.00791	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—PKMYT1—melanoma	0.00243	0.00791	CbGpPWpGaD
Valrubicin—Doxorubicin—ABCB1—melanoma	0.00243	0.0262	CrCbGaD
Valrubicin—Musculoskeletal discomfort—Docetaxel—melanoma	0.00242	0.00439	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—melanoma	0.00238	0.00772	CbGpPWpGaD
Valrubicin—Nausea—Temozolomide—melanoma	0.00237	0.0043	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—E2F1—melanoma	0.00236	0.00767	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—HDAC2—melanoma	0.00234	0.0076	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—GNAQ—melanoma	0.00232	0.00752	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—PCNA—melanoma	0.00223	0.00723	CbGpPWpGaD
Valrubicin—Feeling abnormal—Docetaxel—melanoma	0.00219	0.00397	CcSEcCtD
Valrubicin—Gastrointestinal pain—Docetaxel—melanoma	0.00217	0.00394	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—NGFR—melanoma	0.00214	0.00694	CbGpPWpGaD
Valrubicin—Body temperature increased—Docetaxel—melanoma	0.0021	0.00381	CcSEcCtD
Valrubicin—Abdominal pain—Docetaxel—melanoma	0.0021	0.00381	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—POT1—melanoma	0.00205	0.00665	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDK2—melanoma	0.00204	0.00661	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—melanoma	0.00203	0.00658	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN2B—melanoma	0.00195	0.00633	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDK4—melanoma	0.00192	0.00625	CbGpPWpGaD
Valrubicin—Asthenia—Docetaxel—melanoma	0.00191	0.00345	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—melanoma	0.0019	0.00618	CbGpPWpGaD
Valrubicin—Pruritus—Docetaxel—melanoma	0.00188	0.00341	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—melanoma	0.00185	0.00601	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FGF1—melanoma	0.00183	0.00593	CbGpPWpGaD
Valrubicin—Diarrhoea—Docetaxel—melanoma	0.00182	0.00329	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—E2F1—melanoma	0.00179	0.00581	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PDGFRA—melanoma	0.00177	0.00575	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—melanoma	0.00177	0.00573	CbGpPWpGaD
Valrubicin—Dizziness—Docetaxel—melanoma	0.00176	0.00318	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PRKCA—melanoma	0.00175	0.00569	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FASLG—melanoma	0.00172	0.00558	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—melanoma	0.00171	0.00555	CbGpPWpGaD
Valrubicin—Vomiting—Docetaxel—melanoma	0.00169	0.00306	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PCNA—melanoma	0.00169	0.00548	CbGpPWpGaD
Valrubicin—Rash—Docetaxel—melanoma	0.00168	0.00304	CcSEcCtD
Valrubicin—Dermatitis—Docetaxel—melanoma	0.00167	0.00303	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—RB1—melanoma	0.00167	0.00543	CbGpPWpGaD
Valrubicin—Headache—Docetaxel—melanoma	0.00166	0.00302	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—melanoma	0.00166	0.00538	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RAC1—melanoma	0.00162	0.00527	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—FAS—melanoma	0.00159	0.00516	CbGpPWpGaD
Valrubicin—Nausea—Docetaxel—melanoma	0.00158	0.00286	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK2—melanoma	0.00154	0.00501	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—melanoma	0.00147	0.00478	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—melanoma	0.00146	0.00475	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—melanoma	0.00146	0.00473	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—melanoma	0.00142	0.0046	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—CDK4—melanoma	0.0014	0.00454	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—SKP2—melanoma	0.00137	0.00446	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—APC—melanoma	0.00137	0.00446	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—NOS2—melanoma	0.00136	0.00442	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGF—melanoma	0.00136	0.0044	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN1B—melanoma	0.0013	0.00423	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP8—melanoma	0.00128	0.00415	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—PPARG—melanoma	0.00127	0.00413	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—melanoma	0.00126	0.00408	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—AURKA—melanoma	0.00126	0.00408	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CCND1—melanoma	0.00124	0.00404	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MLH1—melanoma	0.00124	0.00403	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—SKP2—melanoma	0.00123	0.00399	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAP2K1—melanoma	0.00121	0.00394	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—melanoma	0.0012	0.0039	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—melanoma	0.00116	0.00378	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FGF2—melanoma	0.00116	0.00375	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—AURKA—melanoma	0.00112	0.00365	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BCL2—melanoma	0.0011	0.00356	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—APEX1—melanoma	0.00109	0.00354	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—melanoma	0.00108	0.00351	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—melanoma	0.00107	0.00346	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—melanoma	0.00104	0.00338	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—MYC—melanoma	0.000997	0.00324	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	0.000987	0.0032	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—APEX1—melanoma	0.000975	0.00317	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	0.000967	0.00314	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN2B—melanoma	0.000943	0.00306	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	0.000942	0.00306	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	0.000932	0.00303	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	0.000911	0.00296	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	0.000909	0.00295	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	0.000904	0.00294	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—PTEN—melanoma	0.000872	0.00283	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—E2F1—melanoma	0.000866	0.00281	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—PRKCA—melanoma	0.000848	0.00275	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN2B—melanoma	0.000844	0.00274	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	0.000821	0.00267	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—PCNA—melanoma	0.000817	0.00265	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	0.000776	0.00252	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—E2F1—melanoma	0.000774	0.00251	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—PRKCA—melanoma	0.000758	0.00246	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—melanoma	0.000755	0.00245	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDK2—melanoma	0.000747	0.00242	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	0.000739	0.0024	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	0.000739	0.0024	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—PCNA—melanoma	0.00073	0.00237	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDK4—melanoma	0.000706	0.00229	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TERT—melanoma	0.000705	0.00229	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—melanoma	0.000703	0.00228	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	0.000698	0.00227	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDK2—melanoma	0.000668	0.00217	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	0.000641	0.00208	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—ATM—melanoma	0.000634	0.00206	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDK4—melanoma	0.000631	0.00205	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—melanoma	0.00062	0.00201	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—RB1—melanoma	0.000614	0.00199	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—TP53—melanoma	0.000595	0.00193	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—RB1—melanoma	0.000549	0.00178	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—IL6—melanoma	0.000545	0.00177	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—melanoma	0.000539	0.00175	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	0.000524	0.0017	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN2A—melanoma	0.000482	0.00157	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN1B—melanoma	0.000478	0.00155	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MDM2—melanoma	0.000468	0.00152	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CCND1—melanoma	0.000456	0.00148	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN1A—melanoma	0.000441	0.00143	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN1B—melanoma	0.000427	0.00139	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CCND1—melanoma	0.000408	0.00132	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN1A—melanoma	0.000394	0.00128	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MAPK3—melanoma	0.000376	0.00122	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MYC—melanoma	0.000366	0.00119	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MAPK1—melanoma	0.000358	0.00116	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MAPK3—melanoma	0.000336	0.00109	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MYC—melanoma	0.000327	0.00106	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MAPK1—melanoma	0.00032	0.00104	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TP53—melanoma	0.000268	0.000872	CbGpPWpGaD
